Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCH1
- Development stage
- Phase 3
- Lead developer
- National Taiwan University Hospital
- Administration
- Oral
01
Overview
CCH1 is an investigational **six-herb traditional Chinese medicine formulation** developed for chronic constipation in long-term-care residents. It is a modified form of the historical Wen-Pi Tang formula and contains *Panax ginseng*, *Zingiber officinale*, *Glycyrrhiza uralensis*, *Atractylodes macrocephala*, *Aconitum carmichaelii*, and *Rheum tanguticum*. In randomized, double-blind clinical studies in Taiwan, CCH1 was evaluated against placebo and lactulose; it increased spontaneous bowel movements and reduced use of rectal treatments and rescue laxatives. Its molecular targets and precise pharmacologic mechanism have not been established.
- Other names
- mazirenwanhemp seed pillma zi ren wan
02
Targets
AQP3 (Aquaporin-3 channel protein)AQP4 (Aquaporin-4)CHRM3 (M3)
Beyond the preview
Go deeper on CCH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCH1.